Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset
Identifieur interne : 006631 ( Main/Exploration ); précédent : 006630; suivant : 006632Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset
Auteurs : M. Nomoto [Royaume-Uni] ; S. Stahl [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; Marsden [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1987.
English descriptors
- KwdEn :
- (+)‐PHNO, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Administration, Oral, Animals, Antiparkinsonian drugs, Callithrix, Common marmoset, Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Dose-Response Relationship, Drug, Female, Injections, Subcutaneous, MPTP, Male, Motor Activity (drug effects), Motor activity, Oxazines (administration & dosage), Oxazines (therapeutic use), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (drug therapy), Parkinson Disease, Secondary (physiopathology), Pyridines.
- MESH :
- chemical , administration & dosage : Dopamine Agents, Oxazines.
- chemical , therapeutic use : Dopamine Agents, Oxazines.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Pyridines.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Motor Activity.
- drug therapy : Parkinson Disease, Secondary.
- physiopathology : Parkinson Disease, Secondary.
- Administration, Oral, Animals, Callithrix, Dose-Response Relationship, Drug, Female, Injections, Subcutaneous, Male.
Abstract
Administration of MPTP (1–4 mg/kg ip daily for 5–7 days) to common marmosets induced persistent parkinsonian motor deficts. The subcutaneous adminstration of (+)‐PHNO [(+)‐4‐propyl‐9‐hydroxynaphtoxazine; 1–4 μ/kg] caused a dose‐dependent reversal of the akinesia and incoordination of movement. Similarly, oral administration of (+)‐PHNO (5–20 μ/kg) caused an equivalent reversal of the motor abnormalities. No dyskinetic phenomena were induced by (+)‐PHNO on oral or subcutaneous administration. Oral or subcutaneous administration of (+)‐PHNO to normal control marmosets also increased the usual repetoire of motor behaviour, but this was not as marked as in MPTP‐treated animals. (+)‐PHNO is a potent dopamine agonist drug of potential use in the treatment of Parkinson's disease.
Url:
DOI: 10.1002/mds.870020105
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002D04
- to stream Istex, to step Curation: 002D04
- to stream Istex, to step Checkpoint: 004604
- to stream PubMed, to step Corpus: 005093
- to stream PubMed, to step Curation: 005093
- to stream PubMed, to step Checkpoint: 005089
- to stream Ncbi, to step Merge: 004562
- to stream Ncbi, to step Curation: 004562
- to stream Ncbi, to step Checkpoint: 004562
- to stream Main, to step Merge: 009A16
- to stream Main, to step Curation: 006631
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset</title><author><name sortKey="Nomoto, M" sort="Nomoto, M" uniqKey="Nomoto M" first="M." last="Nomoto">M. Nomoto</name></author><author><name sortKey="Stahl, S" sort="Stahl, S" uniqKey="Stahl S" first="S." last="Stahl">S. Stahl</name></author><author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name></author><author><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:32268C2BD22AC6F6A149155A75654CF329014260</idno><date when="1987" year="1987">1987</date><idno type="doi">10.1002/mds.870020105</idno><idno type="url">https://api.istex.fr/document/32268C2BD22AC6F6A149155A75654CF329014260/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002D04</idno><idno type="wicri:Area/Istex/Curation">002D04</idno><idno type="wicri:Area/Istex/Checkpoint">004604</idno><idno type="wicri:doubleKey">0885-3185:1987:Nomoto M:antiparkinsonian:activity:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2904119</idno><idno type="wicri:Area/PubMed/Corpus">005093</idno><idno type="wicri:Area/PubMed/Curation">005093</idno><idno type="wicri:Area/PubMed/Checkpoint">005089</idno><idno type="wicri:Area/Ncbi/Merge">004562</idno><idno type="wicri:Area/Ncbi/Curation">004562</idno><idno type="wicri:Area/Ncbi/Checkpoint">004562</idno><idno type="wicri:doubleKey">0885-3185:1987:Nomoto M:antiparkinsonian:activity:of</idno><idno type="wicri:Area/Main/Merge">009A16</idno><idno type="wicri:Area/Main/Curation">006631</idno><idno type="wicri:Area/Main/Exploration">006631</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset</title><author><name sortKey="Nomoto, M" sort="Nomoto, M" uniqKey="Nomoto M" first="M." last="Nomoto">M. Nomoto</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Research Centre, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill</wicri:orgArea></affiliation></author><author><name sortKey="Stahl, S" sort="Stahl, S" uniqKey="Stahl S" first="S." last="Stahl">S. Stahl</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Merck, Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Harlow, Essex</wicri:regionArea><wicri:noRegion>Essex</wicri:noRegion></affiliation></author><author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Research Centre, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill</wicri:orgArea></affiliation></author><author><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name><affiliation wicri:level="3"><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><wicri:orgArea>MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Research Centre, Institute of Psychiatry and King's College Hospital Medical School, Denmark Hill</wicri:orgArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1987">1987</date><biblScope unit="vol">2</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="37">37</biblScope><biblScope unit="page" to="45">45</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">32268C2BD22AC6F6A149155A75654CF329014260</idno><idno type="DOI">10.1002/mds.870020105</idno><idno type="ArticleID">MDS870020105</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>(+)‐PHNO</term><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Administration, Oral</term><term>Animals</term><term>Antiparkinsonian drugs</term><term>Callithrix</term><term>Common marmoset</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Injections, Subcutaneous</term><term>MPTP</term><term>Male</term><term>Motor Activity (drug effects)</term><term>Motor activity</term><term>Oxazines (administration & dosage)</term><term>Oxazines (therapeutic use)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Parkinson Disease, Secondary (physiopathology)</term><term>Pyridines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agents</term><term>Oxazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agents</term><term>Oxazines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Animals</term><term>Callithrix</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Injections, Subcutaneous</term><term>Male</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Administration of MPTP (1–4 mg/kg ip daily for 5–7 days) to common marmosets induced persistent parkinsonian motor deficts. The subcutaneous adminstration of (+)‐PHNO [(+)‐4‐propyl‐9‐hydroxynaphtoxazine; 1–4 μ/kg] caused a dose‐dependent reversal of the akinesia and incoordination of movement. Similarly, oral administration of (+)‐PHNO (5–20 μ/kg) caused an equivalent reversal of the motor abnormalities. No dyskinetic phenomena were induced by (+)‐PHNO on oral or subcutaneous administration. Oral or subcutaneous administration of (+)‐PHNO to normal control marmosets also increased the usual repetoire of motor behaviour, but this was not as marked as in MPTP‐treated animals. (+)‐PHNO is a potent dopamine agonist drug of potential use in the treatment of Parkinson's disease.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Nomoto, M" sort="Nomoto, M" uniqKey="Nomoto M" first="M." last="Nomoto">M. Nomoto</name></region><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name><name sortKey="Marsden" sort="Marsden" uniqKey="Marsden" last="Marsden">Marsden</name><name sortKey="Stahl, S" sort="Stahl, S" uniqKey="Stahl S" first="S." last="Stahl">S. Stahl</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006631 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006631 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:32268C2BD22AC6F6A149155A75654CF329014260
|texte= Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset
}}
| This area was generated with Dilib version V0.6.23. |  |